Alle Storys
Folgen
Keine Story von Biosign Technologies Inc. mehr verpassen.

Biosign Technologies Inc.

Biosign Receives Reimbursement Approval from NexgenRx

Toronto, March 17, 2010 (ots/PRNewswire)

Biosign Technologies Inc.
(CNSX: BIO) (the "Company" or "Biosign") today  announced it has
received notification that NexgenRx  will  include Biosign's UFIT(R)
device and services into their Benefits Plans for  reimbursement
according to regulatory clearances in the relevant  jurisdiction.
Ronald C. Louks, President & CEO of NexgenRx, said: "We see
diabetic  plan members and their dependents migrating to this
technology very quickly  as they lessen their dependency on the
current invasive monitoring devices.  That alone is reason enough.
However, when you factor in the fractionally  lower cost associated
with the Biosign monthly monitoring charges, compared  to the cost of
the consumable strips that plan sponsors are reimbursing  through
health plans, this becomes even more compelling."
UFIT is Biosign's system for online delivery of health monitoring
services to individuals. All services, including blood pressure and
blood glucose testing, rely on digital representations of the pulse
taken at  the wrist through an inflatable cuff by a portable device
connected to a  computer. The noninvasive, multifunctional monitor
brings an unprecedented  blend of convenience and performance to
self-testing in terms of quality,  access, and cost.
John Anders SVP, Business Development at Biosign, stated: "The
market strength of NexgenRx is derived from combining industry
leading technology  and clinical expertise to deliver better medical
outcomes at lower costs.  We are very pleased to see that NexgenRx is
supportive of our offering as  it fits perfectly into their customer
value proposition."
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include
intelligent systems for noninvasive monitoring of common health risks
associated with blood pressure, glucose, medication. The core
technology  combines measurement, analysis, and rapid knowledge
formation to support  health monitoring across global markets. The
UFIT(R) medical device  technology powers quality data collection and
analytics for clinical  diagnostics, self-care, wellness, disease
state evaluation & management,  and  remote patient monitoring. For
more information on Biosign please  visit http://www.biosign.com.
About NexgenRx
NexgenRx is a growing health benefits management company engaged
in  the design, management and administration of health benefit plans
offered  by employers and other plan sponsors for the benefit of
their employees  and plan members. More information on NexgenRx can
be found  at http://www.nexgenrx.com.
The CNSX has neither approved nor disapproved the contents of
this  press release.
For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: +1(416)218-9800 ext. 234,  Email: 
ceo@biosign.com.

Contact:

CONTACT: For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., Phone: +1(416)218-9800 ext. 234, Email:
ceo@biosign.com.

Weitere Storys: Biosign Technologies Inc.
Weitere Storys: Biosign Technologies Inc.
  • 11.02.2010 – 19:36

    Biosign Certified for Non-invasive Blood Glucose Monitoring

    Toronto (ots/PRNewswire) - Biosign Technologies Inc. (CNSX: BIO) ("Biosign" or the "Company") today announced it has been assessed and certified as meeting the requirements of ISO 9001:2008, ISO 13485-2003, and Directive 93/42/EEC ("CE Mark") for automated wrist blood pressure and blood glucose monitors with computer controls. The certificates allow Biosign to add non-invasive blood glucose monitoring to its offerings ...